AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06311682 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo + TCS
Description: The trial medication will be given under the skin (SC). Dose and dosing frequency for each subject will depend on the subject's body weight. Subjects who will receive treatment every two weeks will receive a loading dose corresponding to a double dose at baseline. Subjects who will receive treatment every 4 weeks will receive a staggered loading dose at baseline and Week 2. After the loading dose, they will continue to receive treatment every 4 weeks. The dose and dosing frequency will be adjusted according to the subject's body weight at weeks 16, 32, 52, 64, 88, 112, 136, 160, and 184.
Study NCT05058508 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Just Move Exercise
Description: Subjects complete Just Move Exercises Five Times Per Week
Study NCT05058508 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard of Care Exercise
Description: Subjects exercise/move as tolerated
Study NCT05034328 — intervention group
Intervention type: DEVICE
Intervention: Healsea® Children
Description: Children will be administered Healsea Children , one puff (1-2 sec) in each nostril twice a day for 10 days on top of conventional therapies, as needed
Study NCT05034328 — intervention group
Intervention type: OTHER
Intervention: Conventional therapies for common cold
Description: Children will receive conventional therapies for common cold, nasal irrigation excluded (antipyretics, mucolytics, decongestants, antitussives, systemic and topical corticosteroids, antibiotics)
Study NCT06255028 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CNTY-101
Description: CNTY-101 cells for intravenous (IV) infusion
Study NCT06255028 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IL-2
Description: IL-2 subcutaneous (SC) injection
Study NCT06255028 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lymphodepleting Chemotherapy
Description: LDC as prespecified in the protocol.
Study NCT04906902 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acalabrutinib
Description: Tablet taken by mouth twice daily
Study NCT04657835 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: cardiac Magnetic Resonance Imaging (MRI)
Description: Cardiac magnetic resonance imaging (MRI) will be realized before Coronary Artery Bypass Grafting for assess atrial cardiomyopathy.
Study NCT04657835 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blood sample
Description: Blood sample will be realized (4 tubes of 4ml blood, 16ml in total) before Coronary Artery Bypass Grafting.
Study NCT04657835 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cardiac muscle biopsy
Description: Cardiac muscle biopsy will be realized during Coronary Artery Bypass Grafting.
Study NCT04657835 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Holter-electrocardiogram (ECG)
Description: Holter-electrocardiogram (ECG) will be realized 1 year after Coronary Artery Bypass Graftin during 3 days to diagnose the occurrence of atrial fibrillation.
Study NCT04657835 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: medical examination
Description: medical examination will be realized 1 year after Coronary Artery Bypass Graftin. Theses datas will collected: events during the follow-up year and evaluation of the Holter-electrocardiogram result.
Study NCT05934851 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Frozen-Section Directed Excision
Description: Frozen-Section Directed Excision (FSDE) is a surgical technique with evaluation of margin status during the surgical procedure, similar to the established Mohs Surgical Technique. The use of FSDE may ensure negative margins, decrease unnecessary excision of healthy tissue and has the potential to greatly reduce positive margins.
Study NCT05934851 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Wide Local Excision
Description: Standard of care surgical technique utilized for VIN 2, VIN3, VIN 2/3 or High-grade Dysplasia NOS
Study NCT06256510 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Participants will receive a single dose of Midazolam by mouth in Period 1 Day 1, and Period 2 Day 1 and Day 15
Study NCT06256510 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vepdegestrant
Description: Participants will receive Vepdegestrant by mouth once a day for 15 days in Period 2.
Study NCT05583578 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Home-based mobility testing and active tDCS
Description: A Soterix Clinical Trials tDCS unit will be used for delivery of stimulation for twenty minutes of 2.0mA direct current through two biocarbon rubber electrodes encased in saline soaked 5cm2 sponges placed over the frontal cortices at F3 and F4 (based on the international 10-20 system of standardized brain electrode placement). 2.0mA was
Study NCT05583578 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham tDCS
Description: Sham stimulation is performed with the same device and all procedures will be identical except for the duration of stimulation. Participants will receive 30 seconds of 2.0mA of direct current stimulation at the beginning of each rehabilitation session. Since participants habituate to the sensation of tDCS within 30-60 seconds of stimulation, this procedure provides the same sensation of active tDCS.
Study NCT05877976 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Visual Arts Immersion
Description: Museum educators from The Metropolitan Museum of Art (MET) will provide a curriculum including an art immersion program that will select specific works/art in the museum as well as virtually that will help to stimulate self-reflection and prompt connection to their nursing practice. Participants will be asked to sign up for 2 art immersion classes. The first class will be an in-person class at The MET and the second class will be virtual via WebEx. Each class will last 60 minutes.
Study NCT05053152 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Administration
Description: Given PO
Study NCT05053152 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT05053152 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT05053152 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Relugolix
Description: Given PO
Study NCT05053152 — intervention group
Intervention type: RADIATION
Group type: PLACEBO_COMPARATOR
Intervention: Stereotactic Body Radiation Therapy
Description: Undergo SABR
Study NCT05053152 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy
Description: Undergo SABR
Study NCT06400992 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cochlear implant processor Sky CITM M90 (CI-5295)
Description: The Sky CI available to included patients (no procedures added) offers the AutoSense Sky OS technology with the three following programming conditions possible. This three condition are fitting and evaluated in noise 6 months after inclusion:~1. Omnidirectional mode : no sound treatment~2. AS Target : Autosense is active and no modifications are made by clinician~3. AS Clinique : Autosense is active and modified by the clinician
Study NCT06400992 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hearing Aid, including sound processor Phonak: Sky Link M90
Description: The device is fitting and programmed for home especially for the purpose research at inclusion. The Clinical map parameters will be verified according to clinical routine.~The Sky Link offers the AutoSense Sky OS technology with the three following programming conditions possible. This three condition are fitting and evaluated in noise 6 months after inclusion:~1. Omnidirectional mode : no sound treatment~2. AS Target : Autosense is active and no modifications are made by clinician~3. AS Clinique : Autosense is active and modified by the clinician
Study NCT06400992 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: French simplified matrix test (FraSimat)
Description: The FraSimat speech in noise test will be tested, 6 months before inclusion in the three different fitting configurations: omni, AS clinic, AS Target. The speech will be presented from the front, noise from 180°. Noise will be presented at a fixed level of 65 dB SPL while the speech signal will be adapted to find the 50% speech reception threshold (SRT).
Study NCT06400992 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Audiologist Fitting Questionnaire
Description: After the fitting of Hearing Aid at inclusion, the audiologist will complete a questionnaire describing the fitting and justifying fitting decisions and will collect the demographic information
Study NCT06400992 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient Satisfaction Questionnaire
Description: The patient will be giving a Patient satisfaction Questionnaire, with questions regarding device and accessory use. The audiologist will go over the instructions for filling out the questionnaire at inclusion. Patients will be asked to complete the questionnaire and return it at the next visit, 6 months after inclusion.
Study NCT06400992 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: AutoSens Feedback Discussion Form
Description: 6 months after inclusion and fitting, the audiologist discusses the use of AS clinic with the subject and completes the AS questionnaire (questionnaire on the experience of using the processor in different listening situations).
Study NCT06172127 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab deruxtecan
Description: 10 mL type 1 amber borosilicate glass vial sealed with a fluoro-resin laminated butyl rubber stopper, and a polypropylene/aluminium yellow flip-off crimp cap. One vial of powder for concentrate for solution for IV infusion contains 100 mg of T-DXd. The drug product also contains L-histidine, L-histidine hydrochloride monohydrate, Sucrose, and Polysorbate 80.
Study NCT06172127 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phesgo 1,200 MG / 600 MG / 30,000 UNT Per 15 ML Injection
Description: 20 mL type I borosilicate glass vial tapered with fluororesin-laminated rubber stopper sealed with aluminum and covered by a cool green plastic flip-off cap, containing 15 mL solution of 1200 mg of pertuzumab and 600 mg of trastuzumab.
Study NCT06172127 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phesgo 600 MG / 600 MG / 20,000 UNT in 10 mL Injection
Description: 15 mL type I borosilicate glass vial tapered with fluororesin-laminated rubber stopper sealed with aluminum and covered by a cool green plastic flip-off cap, containing 10 mL solution of 600 mg of pertuzumab and 600 mg of trastuzumab.
Study NCT05629039 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Volitional Help Sheets
Description: The volitional help sheet is an intervention which provides an opportunity for people to actively plan their behavioural changes by using a list of situations and solutions. The list of situations are critical situations which provoke unwanted behaviour, and the solutions are the responses to overcome the situations which urge the unexpected behaviour. In the context of smoking behaviour, the list of situations is the situations that will provoke cigarette uptake and the list of solutions is the appropriate responses to reduce or stop the urge to smoke.
Study NCT05358145 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tinkering Activities
Description: Tinkering activities are activities that comprise elements of science, art, and technology. Through a series of themes objectives, participants can involve interestingly, creatively, and flexibly in the activity when they fulfill the goal with the materials retrievable at the site. Participants will be trained as they involve in the elements hidden within the core of the training, such as problem exploration, active thinking and inference, trial and error, and problem-solving.
Study NCT05358145 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control Tinkering Activities
Description: Controlled Tinkering Activities utilize the themes of Tinkering activities but eliminate the core of Tinkering training, hence implementing a new set of activities that emphasize participants strictly follow procedures to complete the similar objective of Tinkering activities. Each participant will end up with a similar piece of work as Tinkering Activities participants would without problem exploration, active thinking and inference, trial and error, and problem-solving.
Study NCT05358145 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Board Games Activities
Description: Board games are often constructed with concepts of different cognitive components, such as attention, working memory, planning, calculation; therefore serve as a commonly seen cognitive training, while more and more literature continues to support tabletop games being the medium of cognitive promotion.
Study NCT06383390 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Retatrutide
Description: Administered SC
Study NCT06383390 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered SC
Study NCT06345430 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Exopulse Molli-Suit (Wearable Technological Device)
Description: After initial evaluations, patients will receive Exopulse Mollii Suit in a single session for 1 hour. The stimulation level of the electrodes will be automatically generated by the system in accordance with the pain level specified by the patients for their body parts before the application.
Study NCT05151653 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 765250
Description: BI 765250
Study NCT05151653 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT04835103 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: CM
Description: Case management, a case manager will actively contact and follow the patient's physical and psychological conditions, and provide disease-specific psychoeducation
Study NCT04835103 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: P/T
Description: Psychotherapy, based on both cognitive-behavioral therapy and biofeedback therapy, structuralized, 6-10 sessions, performed by a psychiatrist or psychologist
Study NCT05932836 — intervention group
Intervention type: OTHER
Intervention: No interventions.
Description: No interventions to be administered.
Study NCT05741372 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Description: Rosuvastatin
Study NCT05741372 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Digoxin
Description: Digoxin
Study NCT05741372 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin hydrochlorid
Description: Metformin hydrochloride
Study NCT05741372 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Furosemide
Description: Furosemide
Study NCT05365581 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP2138
Description: Intravenously or Subcutaneously
Study NCT05365581 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Intravenously
Study NCT05365581 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Intravenously
Study NCT05365581 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: Intravenously
Study NCT05365581 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: Intravenously
Study NCT05365581 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramucirumab
Description: Intravenously
Study NCT05365581 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Intravenously
Study NCT05365581 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Intravenously
Study NCT06321302 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 764524
Description: BI 764524
Study NCT06321302 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Sham comparator to BI 764524
Description: Sham comparator to BI 764524
Study NCT06321302 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aflibercept (Eylea®) - US only
Description: Aflibercept (Eylea®) - US only
Study NCT06277934 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RGT001-075
Description: Administered orally
Study NCT06277934 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally
Study NCT06233903 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-mFBG
Description: 18F-mFBG positron emission tomography with CT (PET/CT) or positron emission tomography with MRI (PET/MRI)
Study NCT06274515 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tumor Tissue and Blood Draw
Description: Participants will have their blood drawn on the day a tissue sample is taken from a progressive tumor lesion.
Study NCT05555069 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Menthol-flavored electronic cigarette
Description: Participants will receive 12 weeks of menthol -flavored electronic cigarettes to aid in switching from combustible cigarettes. Participants will be instructed on proper use of the electronic cigarettes, educated about electronic cigarettes and participate in motivation enhancement and substituting electronic cigarettes for cigarettes.
Study NCT05555069 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Tobacco-flavored electronic cigarette
Description: Participants will receive 12 weeks of tobacco-flavored electronic cigarettes to aid in switching from combustible cigarettes. Participants will be instructed on proper use of the electronic cigarettes, educated about electronic cigarettes and participate in motivation enhancement and substituting electronic cigarettes for cigarettes.
Study NCT05930496 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood samples
Study NCT05930496 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biospecimen Collection
Description: Undergo collection of blood samples
Study NCT05930496 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise Intervention
Description: Receive exercise intervention
Study NCT05930496 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise Intervention
Description: Receive tele-coaching intervention
Study NCT05930496 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health Education
Description: Receive health-related information
Study NCT05930496 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Interview
Description: Ancillary studies
Study NCT05930496 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Interview
Description: Ancillary studies
Study NCT05930496 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT05930496 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT05509777 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirikizumab
Description: Administered IV or SC
Study NCT06061770 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Adapted physical activity program
Description: Rehabilitation
Study NCT06061770 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Adapted physical activity self-program
Description: Rehabilitation
Study NCT06192095 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Skin barrier film
Description: Preventive use of skin barrier film after insertion of a vascular indwelling catheter before covering with transparent dressing +/- gauze
Study NCT06640413 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [177Lu]Lu-OncoFAP-23
Description: 3.7, 7.4, or 11.1 GBq to define the RD
Study NCT06640413 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L19IL2
Description: 22.5 Mio IU
Study NCT04949841 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Delgocitinib
Description: Delgocitinib cream 20 mg/g
Study NCT05411887 — intervention group
Intervention type: DRUG
Intervention: Rosuvastatin, Olmesartan Medoxomil
Description: Olostar Tablet
Study NCT04035629 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: MagniXene, hyperpolarized 129Xe MRI
Description: All subjects will undergo hyperpolarized 129-Xenon MR imaging (HP MRI) and conventional proton MR imaging of lung. Hyperpolarized 129Xe gas is prepared in a process termed spin-exchange optical pumping.~Xenon is highly lipophilic and therefore soluble in blood and tissue, making it an excellent tool for imaging the gas in both the air spaces (gas-phase imaging) and dissolved in the lung parenchyma (dissolved-phase imaging). This solubility in combination with xenon's chemical shift properties, results in the possibility of quantifying pulmonary gas exchange and gas transport within the parenchyma.~Additionally, previous images and lung function tests will be reviewed to compare findings and evaluate if there is a correlation between the obtained results.
Study NCT05929599 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% NaCl physiological saline
Description: Nasal-spraying 0.9% NaCl physiological saline is prepared by extracting 5 mL from 0.9% NaCl intravenous infusion 500 mL PP bottle (B.Braun, Germany, product declaration No. VD-32732-19), and then pouring it into the same opaque plastic spraying 10 mL-bottle that is used for LiveSpo Navax.